Outsourcing-Pharma.com presents a very special round-up of the latest movers and shakers in the industry, including news from our own Nick Taylor, as well as updates from Marken, Clarus Therapeutics and Penn Pharma.
Outsourcing-Pharma (OSP) deputy editor Nick Taylor will leave the editorial team this Friday.
A veteran reporter of the pharma and biotech industries, Taylor has worked his way up the ranks on both OSP and in-PharmaTechnologist for the past four years.
He is leaving to take a sabbatical, traveling around the world as a house and dog sitter. He will remain a freelance pharmaceutical journalist as he goes.
Bela Denes has become chief medical officer for Clarus Therapeutics.
He joins the firm from Abbott Laboratories where he was head of therapeutic drug discovery and development efforts in the men’s health division.
Leveraging his 35 year career in urology research, Denes will now focus on developing oral formulations for testosterone replacement therapies, which he says have “enormous market potential.”
Robert Dudley added: "Bela's extensive clinical and industry experience in urology and men's health will be invaluable as CLR-610, our oral testosterone replacement candidate, nears the end of Phase III clinical development.”
Marken has launched its first global advisory board in a bid to promote industry trends and to establish international best practices.
Members include Pharmaceutical Cold Chain Interest Group (PCCIG) chair Rafik Bishara, founder and MD of Supply Chain Operations Laurent Foetisch, Alan Horgan who is an independent consultant working with Whiteacres Associates, and Hedley Rees who is managing consultant for Biotech PharmaFlow.
Together they will provide know-how on regulatory issues, temperature sensitive operations, and clinical specimen aspects of the end-to-end pharma supply chain.
"The drive, passion and energy of this new board will not only propel Marken to new levels, but will also ensure higher standards of patient care by forging new industry expectations for supply chain service,” said CEO Wes Wheeler.
Penn Pharma has made two new appointments to its supply chain team in Colin White and Peter Goold.
White will become head of manufacturing, running the production operations at Penn’s UK facility. In his new role he will implement a new cellular manufacturing structure.
Goold takes the newly created position of director of supply chain and project management all over the world.
CEO Richard Yarwood said: “We are in a period of rapid development both with new personnel and the new facility. Peter and Colin join Penn at an integral point in the company’s growth. Their strong technical backgrounds in their respective areas and vast customer service experience in outsourcing will be a great asset to the Penn brand.”
HCB Health has hired Kathy Field as group creative director.
Field joins the healthcare marketing agency after spending nine years as a freelancer, working mainly with the press departments of Federal agencies, and tech companies.
In her new role she will work on the development of all creative work.
Kerry Hilton, CEO said: “Kathy’s experience in all areas of communications, coupled with solid creative expertise, will be a major asset in servicing our growing number of accounts.”